Page last updated: 2024-12-05

3,5-pyridinedicarboxylic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3,5-Pyridinedicarboxylic acid (3,5-PDA) is a heterocyclic dicarboxylic acid that has garnered significant research interest due to its potential applications in diverse fields. It is a white solid, soluble in water and polar organic solvents. The compound can be synthesized through various methods, including the oxidation of 3,5-dimethylpyridine using potassium permanganate or chromic acid. 3,5-PDA exhibits remarkable coordination properties, forming stable complexes with various metal ions. Its ability to act as a chelating agent has led to investigations in areas like catalysis, where it serves as a ligand for transition metal catalysts in various organic reactions. The compound also shows potential in the development of luminescent materials, due to its fluorescence properties, and has been explored for its use in sensors and optical devices. Additionally, 3,5-PDA has been studied for its potential biological activity, showing promising results as a potential antimicrobial agent and inhibitor of certain enzymes. Research on 3,5-PDA continues to explore its various applications, driven by its versatility and potential for advancement in fields like catalysis, materials science, and medicine.'

3,5-pyridinedicarboxylic acid: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10366
CHEMBL ID446761
CHEBI ID46875
SCHEMBL ID51830
MeSH IDM0542290

Synonyms (58)

Synonym
AC-2844
einecs 207-893-8
ai3-52669
nsc 6497
unii-n5nmh4pz3d
n5nmh4pz3d ,
bdbm26118
pyridine carboxylate, 6f
nsc-6497
pyridine-3,5-dicarboxylic acid
3,5-pyridinedicarboxylic acid
dinicotinic acid
5-carboxynicotinic acid
499-81-0
nsc6497 ,
NCI60_017340
TIMTEC1_000362
NCGC00013071
OPREA1_413127
STK301573
SR-01000640386-1
3,5-pyridinedicarboxylic acid, 98%
NCI6497
CHEBI:46875 ,
NCISTRUC1_000161
NCISTRUC2_000049
NCGC00096195-01
HMS1535A10
AKOS000277471
P0551
CHEMBL446761
A7430
pyridine-3,5-dicarboxylic acid;3,5-pyridinedicarboxylic acid
3,5-dipyridinecarboxylic acid
CCG-37624
NCGC00013071-02
BP-12521
FT-0614745
AM20070057
AB00376196-04
SCHEMBL51830
FG-0462
5-carboxy nicotinic acid
mfcd00006393
SY003098
dinicotinic acid-3,5-pyridinedicarboxylic acid
W-105997
Z275127642
DTXSID10198149
CS-W002000
3,5-pyridinedicarboxylic acid, vetec(tm) reagent grade, 98%
NCGC00013071-03
Q15632703
3,5-dipicolinic acid
EN300-42792
pyridine-3,5-dicarboxylicacid
3,5-pyridine dicarboxylic acid
HY-W002000
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
pyridinedicarboxylic acidAny member of the class of pyridines carrying two carboxy groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Lysine-specific demethylase 4EHomo sapiens (human)IC50 (µMol)10,000.00000.20001.95696.3096AID1798635
D-aspartate oxidaseHomo sapiens (human)IC50 (µMol)10,000.00000.00400.39370.8550AID1247843
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (9)

Processvia Protein(s)Taxonomy
regulation of gene expressionLysine-specific demethylase 4EHomo sapiens (human)
chromatin remodelingLysine-specific demethylase 4EHomo sapiens (human)
inseminationD-aspartate oxidaseHomo sapiens (human)
grooming behaviorD-aspartate oxidaseHomo sapiens (human)
regulation of cell communicationD-aspartate oxidaseHomo sapiens (human)
D-amino acid catabolic processD-aspartate oxidaseHomo sapiens (human)
hormone metabolic processD-aspartate oxidaseHomo sapiens (human)
nervous system processD-aspartate oxidaseHomo sapiens (human)
aspartate catabolic processD-aspartate oxidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
metal ion bindingLysine-specific demethylase 4EHomo sapiens (human)
histone H3K9me2/H3K9me3 demethylase activityLysine-specific demethylase 4EHomo sapiens (human)
histone H3K9 demethylase activityLysine-specific demethylase 4EHomo sapiens (human)
protein bindingD-aspartate oxidaseHomo sapiens (human)
D-aspartate oxidase activityD-aspartate oxidaseHomo sapiens (human)
D-glutamate oxidase activityD-aspartate oxidaseHomo sapiens (human)
FAD bindingD-aspartate oxidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Processvia Protein(s)Taxonomy
nucleusLysine-specific demethylase 4EHomo sapiens (human)
nucleoplasmLysine-specific demethylase 4EHomo sapiens (human)
chromatinLysine-specific demethylase 4EHomo sapiens (human)
nucleusLysine-specific demethylase 4EHomo sapiens (human)
peroxisomeD-aspartate oxidaseHomo sapiens (human)
peroxisomeD-aspartate oxidaseHomo sapiens (human)
peroxisomal matrixD-aspartate oxidaseHomo sapiens (human)
cytosolD-aspartate oxidaseHomo sapiens (human)
cytoplasmD-aspartate oxidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID1224817Assays to identify small molecules inhibitory for eIF4E expression2015Chemistry & biology, Jul-23, Volume: 22, Issue:7
Internal Ribosome Entry Site-Based Bicistronic In Situ Reporter Assays for Discovery of Transcription-Targeted Lead Compounds.
AID1798635FDH Coupled Inhibition Assay from Article 10.1021/jm800936s: \\Inhibitor Scaffolds for 2-Oxoglutarate-Dependent Histone Lysine Demethylases.\\2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Inhibitor scaffolds for 2-oxoglutarate-dependent histone lysine demethylases.
AID344916Inhibition of 2-oxoglutarate-dependent human JMJD2E in presence of excess 2-oxoglutarate and 10 uM Fe2 by FDH coupled assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Inhibitor scaffolds for 2-oxoglutarate-dependent histone lysine demethylases.
AID1247844Inhibition of human recombinant DAO expressed in Escherichia coli BL21(DE3) using D-Asp and D-Ala assessed as 2-oxo acid production after 10 mins by colorimetric assay2015Journal of medicinal chemistry, Sep-24, Volume: 58, Issue:18
Identification of Novel D-Aspartate Oxidase Inhibitors by in Silico Screening and Their Functional and Structural Characterization in Vitro.
AID344917Inhibition of 2-oxoglutarate-dependent human JMJD2E in presence of excess H3K9me3 peptide and 10 uM Fe2 by FDH coupled assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Inhibitor scaffolds for 2-oxoglutarate-dependent histone lysine demethylases.
AID1247843Inhibition of human recombinant DDO expressed in Escherichia coli BL21(DE3) using D-Asp and D-Ala assessed as 2-oxo acid production after 10 mins by colorimetric assay2015Journal of medicinal chemistry, Sep-24, Volume: 58, Issue:18
Identification of Novel D-Aspartate Oxidase Inhibitors by in Silico Screening and Their Functional and Structural Characterization in Vitro.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (25.00)29.6817
2010's6 (75.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.15

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.15 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index31.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.15)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]